Strategic Relationships

BioAtla’s strategy is to advance a large portfolio of CABs in a variety of formats that can be used individually and in combinations to best treat particular cancer indications. We are very selective in our partnerships and ideally will take our drug candidates through clinical proof of concept before partnering. Our relationship with Pfizer provides us with access to high quality ADC technology for our drugs. In addition, the companies are working together to advance a CAB immune checkpoint inhibitor and selected CAB-ADCs into commercial products and markets around the world. Similarly, our partnership with Sinobioway supports a comprehensive strategy to address the second largest pharmaceutical market in the world, China, while providing a continuous source of funding for the development of new drug candidates.

Pfizer and BioAtla® have entered into a license and option agreement to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla®’s CAB platform and utilizing Pfizer’s proprietary antibody drug conjugate (ADC) payloads. CAB-ADC antibodies aim to enable the preferential targeting of tumor tissues by ADCs, thereby increasing the efficacy-safety ratios of CAB-ADCs relative to their conventional counterparts. Pfizer also gains an exclusive option to develop and commercialize BioAtla® CAB antibodies that target CTLA4, a validated immuno-oncology target in humans. For more information see News.

Beijing Sinobioway Group Company, Ltd was founded in 1992 and is one of the three main industrial groups affiliated with Peking University. Sinobioway is a leader in the development of the bioeconomy in China, including investments in biomedicine, bioagriculture, bioenergy, bioenvironment, bioservices, biomanufacturing and biointelligence. The development and commercialization of biologic therapeutics is a particular focus of Sinobioway, including the construction of a large biologics manufacturing facility in the new bio-economic zone in Hefei.

BioAtla® and Sinobioway have a strategic partnership to develop and commercialize select CAB antibodies and other CAB-based therapeutics for the Chinese market, helping to address the growing demand in China for innovative therapeutic products. For more information see News.